High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Dyslipidemia
Interventions:   Drug: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.;   Drug: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
Sponsor:   Ache Laboratorios Farmaceuticos S.A.
Completed

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: Evinacumab;   Drug: Matching placebo;   Other: Background Lipid Modifying Therapy (LMT)
Sponsor:   Regeneron Pharmaceuticals
Recruiting

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug: Lovastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Condition:   Homozygous Familial Hypercholesterolemia
Intervention:   Drug: Evinacumab
Sponsor:   Regeneron Pharmaceuticals
Not yet recruiting

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

Condition:   Homozygous Familial Hypercholesterolemic
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting

Long Term Safety Study of PRALUENT

Conditions:   Heterozygous Familial Hypercholesterolemia;   Non-familial Hypercholesterolemia
Intervention:   Drug: Praluent
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Enrolling by invitation

Study to Evaluate the Safety of Repatha® in Pregnancy

Conditions:   Hypercholesterolaemia;   Pregnancy
Intervention:  
Sponsor:   Amgen
Recruiting

Chart Review of Repatha® in Subjects With Hyperlipidaemia

Condition:   Hypercholesterolaemia
Intervention:  
Sponsor:   Amgen
Recruiting

The Efficacy of Cholesterol-lowering Probiotic Lactobacillus Plantarum LPLDL® in Hypercholesterolemic Adults.

Condition:   Hypercholesterolemia
Interventions:   Dietary Supplement: Lactobacillus plantarum ECGC 13110402;   Dietary Supplement: Placebo Comparator: Maltodextrin
Sponsor:   University of Roehampton
Recruiting

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Condition:   Hypercholesterolemia
Intervention:   Drug: CIVI 007
Sponsor:   Civi Biopharma, Inc.
Active, not recruiting

Effects of Atorvastatin in Graves' Orbitopathy (GO)

Conditions:   Thyroid Associated Ophthalmopathy;   Hypercholesterolemia
Interventions:   Drug: Atorvastatin;   Drug: Methylprednisolone
Sponsor:   University of Pisa
Not yet recruiting

A Cholesterol Lowering Therapy of Non-invasive Focused High-intensity Ultrasound Mediated Perirenal Fat Modification

Conditions:   Hypercholesteremia;   Dyslipidemias;   Arteriosclerotic Cardiovascular Disease
Interventions:   Procedure: High-intensity focused ultrasound mediated perirenal fat modification;   Procedure: Sham control procedure
Sponsor:   Xiangqing Kong
Not yet recruiting

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

Condition:   Hypercholesterolemia
Interventions:   Combination Product: EZ 10 mg/Ator 10 mg;   Combination Product: EZ 10 mg/Ator 20 mg;   Drug: Atorvastatin;   Drug: Placebo for FDC EZ/Ator;   Drug: Placebo for atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting

Plant Sterol INtervention for Cancer Prevention (PINC)

Conditions:   Hypercholesterolemia;   Breast Cancer;   Obesity
Interventions:   Dietary Supplement: Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd);   Dietary Supplement: Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)
Sponsors:   University of Leeds;   The Leeds Teaching Hospitals NHS Trust;   University of Oslo
Not yet recruiting

Multiple Chronic Conditions for Older Adults

Condition:   Chronic Disease
Interventions:   Other: Treatment as usual (TAU) + Internet;   Behavioral: TAU + ElderTree
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin Hospital and Clinics (UW Health);   Medical University of South Carolina;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation

Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E

Condition:   Fatty Liver
Interventions:   Drug: Vitamin E 200 IU/d;   Drug: Vitamin E 400 IU/d;   Drug: Vitamin E 800 IU/d;   Behavioral: Diet and Exercise
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population

Conditions:   Dyslipidemias;   Atherosclerosis;   Households;   Survey, Family Life
Intervention:  
Sponsors:   Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose;   Biochimie Clinique LR99ES11;   Department of Biochemistry, La Rabta Hospital, Tunisia.;   Ministry of Health, Tunisia;   Ministry of Interior, Tunisia;   Direction des Soins de Santé de Base;   National Institute of Statistics;   National Institute of Public Health of Tunisia;   Dacima Consulting
Completed

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Conditions:   Stroke;   Intracranial Atherosclerosis;   Intraplaque Hemorrhage
Interventions:   Drug: Alirocumab;   Drug: Placebo
Sponsors:   University of Utah;   Regeneron Pharmaceuticals
Recruiting

Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System

Condition:   Focal Segmental Glomerulosclerosis
Intervention:   Device: LIPOSORBER® LA-15
Sponsor:   Kaneka Pharma America LLC
Recruiting

Promoting Patient Engagement in Clinical Preventive Services: Evaluating the Use of Healthfinder

Condition:   Health Knowledge, Attitudes, Practice
Intervention:   Other: Healthfinder invitation
Sponsor:   Virginia Commonwealth University
Completed

Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada

Condition:   Dyslipidemia
Intervention:   Other: survey
Sponsors:   Canadian Heart Research Centre;   Amgen
Completed

DISCOVER Global Registry

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting